Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06621979

Evaluation of the Fundoplicature of the Excluded Stomach Post Omega Bypass

The purpose of this study is to evaluate the efficacy of fundoplication with stomach excluded in the suppression of disabling gastroesophageal reflux requiring surgery in patients who have undergone one anastomosis gastric bypass, with complete objective evaluation of reflux.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The FEE& RGOIC trial is a single-center, ambispective, interventional, non-randomized pilot study to evaluate the efficacy of Fundoplicature with stomach excluded objectively and comprehensively in the treatment of disabling gastroesophageal reflux requiring gastric bypass after anastomosis.

The strategy under study is objective reflux suppression after fundoplication with the stomach excluded in the following specific context: treatment of disabling gastroesophageal reflux requiring post-bypass surgery in Omega.

The eligible study population will be any adult patient at the investigating center who has undergone one-anastomosis gastric bypass surgery followed by fundoplication of the excluded stomach as part of treatment for disabling post-bypass gastro-oesophageal reflux, resistant to medical treatment and requiring surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years;
  • Patient operated for one anastomosis gastric bypass followed by Fundoplicature with stomach excluded for disabling gastroesophageal reflux requiring surgery within 2 years prior to inclusion;
  • Patient in failure of medical treatment;
  • Weight loss greater than 50% of excess weight;
  • Patient with preoperative objective investigations (gastrojejunal fibroscopy, ph-impedancemetry, abdominal CT scan) of gastroesophageal reflux disease;
  • Patient able to understand study-related information and to complete quality-of-life questionnaires in the opinion of the investigator;
  • Patient willing to accept study evaluations;
  • For women of childbearing age, effective contraception for the duration of the study or negative blood pregnancy test;
  • Patient has been informed and has given free, informed and written consent.

Exclusion criteria

  • Patient with conversion from one anastomosis gastric bypass to Y bypass for disabling gastroesophageal reflux requiring surgery;
  • Patient with concomitant hiatal hernia correction for one anastomosis gastric bypass ;
  • Patient with secondary one anastomosis gastric bypass ;
  • Patient with a deregulated diet;
  • Patient under legal protection, or deprived of liberty by judicial or administrative decision;
  • Patient unable to understand study information for linguistic, psychological, cognitive or other reasons;
  • Women who are or may become pregnant, of childbearing age, without effective contraception or who are breast-feeding;
  • Patient participating in another clinical trial, or in a period of exclusion from another clinical trial that could interfere with the results of the present study;
  • Patient not covered by a social security scheme.

Treatment and study plan

Bypass surgery type one anastomosis gastric bypass

Procedure

Adult patients who have undergone single-anastomosis gastric bypass followed by fundoplication of the excluded stomach for the treatment of disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgical intervention.

Primary outcomes

  1. Response rate after Fundoplicature with stomach excluded

    Time frame: 2 years

    The primary endpoint is the long-term efficacy of Fundoplicature with stomach excluded in the treatment of disabling Gastroesophageal Reflux Disease requiring Omega post-bypass surgery after surgery.

Study contacts

Contact information is provided by the study sponsor or research team.

Arnaud LIAGRE, MD

CONTACT

[email protected]

0562132758 ext. + 33

Sponsors and collaborators

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche

Other

Collaborators

  • Euraxi Pharma

Registry information

Official study title

Evaluation of Post-Omega Bypass Excluded Stomach Fundoplication to Treat Disabling Gastroesophageal Reflux Disease Resistant to Medical Treatment and Requiring Surgery

Acronym: FEE-RGOIC

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 1, 2024
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.